Page 302 - Drug Class Review

Page 181 of 205
Drug Effectiveness Review Project

placebo NR 4% 7% 0% placebo 10.5% 6.5%

tacrine NR 44% 33% 10% Post randomization exclusions: NR Overall loss to follow-up: 20.1% Loss to follow-up differential high: Yes tacrine 29.5% 23%

ITT: No

NR NR NR Yes Poor

Final Report Update 1 Authors: Wood et al. Year:1994 ADVERSE EVENTS: Overall adverse effects reported: Raised LFTs • Nausea/Vomiting • Dizziness • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs